Rereading the annual report and a few thoughts regarding impending announcements for a good and sustained SP rise in 2017 (some 1st half of 2017):
- Penthrox sales launch in France and Belgium
- Regulatory approval submitted for a further 22 European countries (How many approved? 20/22? Half?)
- Respiratory deals coming to fruition in US, Canada and Europe
- NO DEBT
Even forgetting the veterinary side of MVP, how big is the potential here? Revenue wise and SP growth? What about the publication of positive results in the multiple trials as outlined in the annual report?
In any case, I took my profits out of oil and reinvested them into MVP. In my mind, this is a no-brainer: the capacity to saturate world-wide markets with Penthrox and their respiratory devices......sheesh.....I may need to keep accumulating for that early retirement.
Most Valuable Player 2017
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $34.52M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 40.0¢ | $3.981K | 9.899K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 62022 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 815 | 2 |
View Market Depth
| Last trade - 15.59pm 04/07/2024 (20 minute delay) ? |
| MVP (ASX) Chart |